Increasing numbers of pregnant women are prescribed selective serotonin (5-HT) reuptake inhibitor (SSRI) antidepressants to treat depression during pregnancy. SSRI treatment in early pregnancy has recently been associated with increased risk of adverse effects such as autism spectrum disorder (ASD) later in offspring life. Adverse effects are not avoided by foregoing therapy, as untreated depression and the associated maternal stress affect offspring neurological outcomes. Additionally, epidemiological studies cannot clearly separate medication from maternal disease effects on the developing offspring brain. The goal of this project is to dissociate mechanistically the short- and long-term effects of exposure to maternal stress and to SSRIs on fetal brain development and adult function using a mouse model.
The first aim determines the specific parameters of fetal brain exposure to SSRIs and their metabolites, including influence of gestational age, dosage, duration of exposure and identity of the drug. Experiments proposed in this aim take advantage of a newly developed methodology for studying placental drug transport; this unique expertise will permit us to measure bi-directional drug transport between mother and fetus, as well as placental drug accumulation and metabolism at different stages of pregnancy.
The second aim i nvestigates the effect of prenatal exposure to maternal stress and commonly used SSRIs (alone and in combination) on fetal brain structure, neurochemistry and serotonergic and thalamocortical neuronal pathway formation. Experiments combine new high-resolution whole fetal brain diffusion magnetic resonance imaging (in collaboration with Dr Irina Burd at Johns Hopkins University), biochemistry and immunohistochemistry to investigate the effects of timing and duration of exposure on structure and neuronal circuit formation in situ.
The third aim determines the long-term effects of maternal stress and SSRI exposure at different times of gestation on adult offspring brain function. The proposed experiments use recent advances in highly time-resolved microdialysis (in collaboration with Dr Anne Andrews at UCLA) to determine changes in basal and stimulated extracellular 5-HT levels in ventral hippocampus in awake adult male and female offspring. Relevance to public health: The proposed studies address an urgent need for the investigation of fetal developmental risks that stem from maternal stress/depression and/or its pharmacological treatment during pregnancy, while further defining prenatal sensitive periods that influence complex biological interactions between the mother, placenta and fetal brain. In the long term this research is expected to lead to improved risk assessment, and to help to develop safer therapeutic strategies for pregnant women and their offspring.
The goal of this project is to dissociate mechanistically the short- and long-term effects of exposure to maternal stress and to selective serotonin reuptake inhibitor antidepressants (SSRIs) on fetal brain development and adult function using a mouse model. Through the complementary expertise of three different research groups, we propose three aims that will advance our understanding of maternal-fetal SSRI transfer, fetal brain drug exposure, and the short- and long-term consequences of SSRI exposure alone and combined with maternal stress on the development and function of brain circuits that are implicated in psychiatric disorders.
